Re-runs extraction for each period with period-end year from max(2023, current year − 2) through the current year, oldest first (up to three reporting years). This can take a long time.
Pharmaceutical innovation—diabetes, obesity, oncology, immunology, and neuroscience therapies.
Sector: Health care
US_LLY
No intraday sparkline from the default exchange feed; Yahoo or day change may still appear below when available.
No price chart.
Net debt (table and EV/EBITDA): |short-term borrowings| + |long-term borrowings| + |other financial liabilities| when extracted + |non-controlling interest| when extracted − |cash and equivalents|; amounts in millions of the reporting currency.
Shares: sec_companyfacts/59478
| Period | Issues |
|---|---|
| 2023-03-31 Q1 | ✗Errors 2Warn 1 |
| 2023-06-30 Q2 | ✗Errors 1Warn 1 |
| 2023-09-30 Q3 | ✗Errors 1Warn 3 |
| 2023-12-31 FY | ✗Errors 1Warn 1 |
| 2024-03-31 Q1 | ⚠Warn 1 |
| 2024-06-30 Q2 | ✗Errors 1Warn 1 |
| 2024-09-30 Q3 | ✗Errors 1Warn 1 |
| 2024-12-31 FY | ⚠Warn 1 |
| 2025-03-31 Q1 | ⚠Warn 1 |
| 2025-06-30 Q2 | ✗Errors 1Warn 1 |
| 2025-09-30 Q3 | ✗Errors 1Warn 1 |
| 2025-12-31 FY | ⚠Warn 1 |
| 2026-03-31 Q1 | ⚠Warn 1 |
Monetary columns are in B USD, one decimal; scale (K/M/B/T) keeps values readable. For the period (default) shows P&L and cash flow for that row’s reporting window: quarterly amounts when the feed uses quarter-duration facts (typical US 10-Q revenue and income), quarterly cash flows after stripping YTD where only cumulative tags exist, and an implied Q4 on 31 Dec FY rows (P&L: FY minus Q1–Q3; operating / investing cash flow: FY 12m minus 9M YTD to 30 Sep when sourced from SEC builder evidence) so they match 10-Q scale. Some issuers still use cumulative YTD minus the prior row in the same calendar year. As reported shows values stored on each row (e.g. full-year on FY). Balance sheet is always as reported. Source JSON may use millions etc.; conversion uses amounts_unit per row.
| Date | Period | Status | RevenueB USD | Operating profitB USD | D&AB USD | EBITDAB USD | Net profitB USD | Operating CFB USD | Capex + M&AB USD | AssetsB USD | EquityB USD | ROE (annualized) | Net debtB USD | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | Q1 2026 (3M) | OK | 19.8 y/y 55.5% | 8.8 y/y 156.1% | 0.5 y/y 9.9% | 9.4 y/y 138.8% | 7.4 y/y 168.1% | 5.3 | -3.9 | 116.6 y/y 30.4% | 31.2 y/y 97.9% | 102.5% | 38.1 | Link |
| 2025-12-31 | FY 2025 (12M) | OK | 19.3 y/y 42.6% | 8.3 y/y 64.1% | 0.6 y/y 20.7% | 8.9 y/y 60.3% | 6.6 y/y 50.5% | 3.2 | -2.8 | 112.5 y/y 42.9% | 26.5 y/y 85.9% | 82.0% | 35.5 | Link |
| 2025-09-30 | Q3 2025 (3M) | OK | 17.6 y/y 53.9% | 7.2 y/y 355.3% | 0.5 y/y 0.7% | 7.7 y/y 274.8% | 5.6 y/y 475.3% | 8.8 | -3.0 | 114.9 y/y 52.0% | 23.8 y/y 67.1% | 35.4% | 32.7 | Link |
| 2025-06-30 | Q2 2025 (3M) | OK | 15.6 y/y 37.6% | 6.8 y/y 92.7% | 0.5 y/y 15.4% | 7.3 y/y 84.5% | 5.7 y/y 90.8% | 3.1 | -1.8 | 100.9 y/y 40.4% | 18.3 y/y 34.7% | 133.0% | 36.5 | Link |
| 2025-03-31 | Q1 2025 (3M) | OK | 12.7 y/y 45.2% | 3.5 y/y 36.3% | 0.5 y/y 15.6% | 3.9 y/y 33.4% | 2.8 y/y 23.0% | 1.7 | -3.4 | 89.4 y/y 39.8% | 15.8 y/y 23.0% | 73.5% | 35.4 | Link |
| 2024-12-31 | FY 2024 (12M) | OK | 13.5 y/y 44.7% | 5.0 y/y 100.9% | 0.5 y/y 25.2% | 5.5 y/y 90.8% | 4.4 y/y 101.4% | 2.5 | -1.9 | 78.7 y/y 23.0% | 14.3 y/y 32.5% | 74.3% | 30.6 | Link |
| 2024-09-30 | Q3 2024 (3M) | OK | 11.4 y/y 20.4% | 1.6 y/y 271.8% | 0.5 y/y 13.6% | 2.1 y/y 145.2% | 1.0 y/y 1790.4% | 3.7 | -4.0 | 75.6 y/y 30.5% | 14.2 y/y 26.9% | 9.3% | 27.8 | Link |
| 2024-06-30 | Q2 2024 (3M) | OK | 11.3 y/y 36.0% | 3.5 y/y 68.4% | 0.4 y/y 13.1% | 3.9 y/y 60.1% | 3.0 y/y 68.3% | 1.5 | -2.2 | 71.9 y/y 31.1% | 13.6 y/y 22.6% | 90.0% | 25.7 | Link |
| 2024-03-31 | Q1 2024 (3M) | OK | 8.8 y/y 26.0% | 2.5 y/y 65.8% | 0.4 y/y 10.6% | 2.9 y/y 55.2% | 2.2 y/y 66.8% | 1.2 | -1.2 | 63.9 y/y 20.3% | 12.8 y/y 14.5% | 76.1% | 23.8 | Link |
| 2023-12-31 | FY 2023 (12M) | OK | 9.4 y/y — | 2.5 y/y — | 0.4 y/y — | 2.9 y/y — | 2.2 y/y — | -0.3 | -2.9 | 64.0 y/y — | 10.8 y/y — | 47.7% | 22.6 | Link |
| 2023-09-30 | Q3 2023 (3M) | OK | 9.5 y/y — | 0.4 y/y — | 0.4 y/y — | 0.8 y/y — | -0.1 y/y — | 2.2 | -3.1 | 57.9 y/y — | 11.2 y/y — | -0.7% | 17.8 | Link |
| 2023-06-30 | Q2 2023 (3M) | OK | 8.3 y/y — | 2.1 y/y — | 0.4 y/y — | 2.5 y/y — | 1.8 y/y — | 0.6 | -0.5 | 54.8 y/y — | 11.1 y/y — | 63.4% | 16.1 | Link |
| 2023-03-31 | Q1 2023 (3M) | OK | 7.0 y/y — | 1.5 y/y — | 0.4 y/y — | 1.9 y/y — | 1.3 y/y — | 1.7 | -0.7 | 53.2 y/y — | 11.2 y/y — | — | 15.3 | Link |
Quarterly values ($ mln)
Year-over-year change
Net debt / cash ($ mln)
Current 31.9x · 3-year average 52.0x
No dividend rows found for this issuer (checked: Yahoo Finance (ex-div)).
Reporting forms detected in loaded periods: ✓ ✓ ✓ (Balance sheet / Profit or loss (P&L) / Cash flows)